Bristol Myers Squibb (NYSE:BMY) announces the
commercial launch of Zeposia (ozanimod) 0.92 mg for the once-daily oral
treatment of adults with relapsing forms of multiple sclerosis (MS),
including clinically isolated syndrome, relapsing-remitting disease and
active secondary progressive disease.
The FDA approved the product on March 25.
https://seekingalpha.com/news/3578930-bristol-myers-launches-ms-med-zeposia-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.